Table 2

Summary of base-case analyses

Rezvilutamide plus ADTBicalutamide plus ADTIncremental
Total cost (US$)106 807.7446 048.9260 758.82
 Drug cost79 345.0816 148.6863 196.40
 AEs management cost56.0555.910.14
 Disease management cost4749.112410.632338.48
 Subsequent treatment cost22 609.6427 433.69−4824.26
QALYs6.083.802.28
ICER (US$/QALY)26 656.94
  • ADT, androgen deprivation therapy; AEs, adverse events; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.